Market Cap 903.48M
Revenue (ttm) 89.15M
Net Income (ttm) 8.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 8.97%
Debt to Equity Ratio 1.14
Volume 942,011
Avg Vol 1,470,916
Day's Range N/A - N/A
Shares Out 98.85M
Stochastic %K 61%
Beta 0.79
Analysts Strong Sell
Price Target $27.20

Company Profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 858 771 9307
Address:
11682 El Camino Real, Suite 120, San Diego, United States
Stone52
Stone52 Feb. 26 at 9:20 PM
$SPRY stock finally looks good from a technical basis. Hopefully, we’ve seen the last of the 8’s. News on the horizon includes earnings, investment bank presentations and expected Canada approval before the end of March.
0 · Reply
G101SPM
G101SPM Feb. 26 at 7:54 PM
#SHOWTIME American Academy of Allergy Asthma and Immunology Meeting (February 27 - March 1) Scheduled to appear: $COGT, $DBV, $ENTA, $PHVS, $SPRY
0 · Reply
ThinkVision
ThinkVision Feb. 26 at 4:29 PM
$AQST $SPRY neffy, adrenaline nasal spray, now approved to treat anaphylaxis in Australia
2 · Reply
ThinkVision
ThinkVision Feb. 26 at 4:25 PM
$SPRY $AQST https://newsroom.csl.com/2026-02-15-neffy,-adrenaline-nasal-spray,-now-approved-to-treat-anaphylaxis-in-Australia
0 · Reply
Stone52
Stone52 Feb. 26 at 1:10 PM
$SPRY Viatris earnings out this morning. Epi Pen sales were up in Q4 vs year ago and up 2025 vs 2024.
0 · Reply
Stone52
Stone52 Feb. 26 at 1:06 PM
0 · Reply
Ravery
Ravery Feb. 26 at 3:06 AM
$SPRY Stone isn't it time for a short interest update? You so graciously flooded the aqst board with constant short interest updates. If I recall the rise in SI was due to "big boy" positioning. What is happening with SPRY? How are the big boys positioning here?
1 · Reply
BigGainTom
BigGainTom Feb. 25 at 9:23 PM
$SPRY short interest up by 1M shares. $AQST Short interest down by 300k shares.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 1:20 PM
$SPRY RSI: 36.31, MACD: -0.3767 Vol: 0.51, MA20: 9.68, MA50: 10.48 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
prototyper
prototyper Feb. 24 at 8:31 PM
$SPRY Volume less than 500K. Expecting ER to be catastrophically bad. GL cuz you will need it
1 · Reply
Latest News on SPRY
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock

Jan 9, 2026, 12:32 PM EST - 6 weeks ago

Bad News For Competitor Turns Into Big Win For ARS Pharma Stock


ARS Pharmaceuticals: A Significant Upside Is Expected From neffy

Sep 23, 2025, 2:08 AM EDT - 5 months ago

ARS Pharmaceuticals: A Significant Upside Is Expected From neffy


ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 11:53 AM EDT - 7 months ago

ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript


ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript

May 14, 2025, 1:32 PM EDT - 10 months ago

ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript


ARS Pharmaceuticals Has A Blockbuster Candidate

Apr 30, 2025, 6:51 AM EDT - 10 months ago

ARS Pharmaceuticals Has A Blockbuster Candidate


Stone52
Stone52 Feb. 26 at 9:20 PM
$SPRY stock finally looks good from a technical basis. Hopefully, we’ve seen the last of the 8’s. News on the horizon includes earnings, investment bank presentations and expected Canada approval before the end of March.
0 · Reply
G101SPM
G101SPM Feb. 26 at 7:54 PM
#SHOWTIME American Academy of Allergy Asthma and Immunology Meeting (February 27 - March 1) Scheduled to appear: $COGT, $DBV, $ENTA, $PHVS, $SPRY
0 · Reply
ThinkVision
ThinkVision Feb. 26 at 4:29 PM
$AQST $SPRY neffy, adrenaline nasal spray, now approved to treat anaphylaxis in Australia
2 · Reply
ThinkVision
ThinkVision Feb. 26 at 4:25 PM
$SPRY $AQST https://newsroom.csl.com/2026-02-15-neffy,-adrenaline-nasal-spray,-now-approved-to-treat-anaphylaxis-in-Australia
0 · Reply
Stone52
Stone52 Feb. 26 at 1:10 PM
$SPRY Viatris earnings out this morning. Epi Pen sales were up in Q4 vs year ago and up 2025 vs 2024.
0 · Reply
Stone52
Stone52 Feb. 26 at 1:06 PM
0 · Reply
Ravery
Ravery Feb. 26 at 3:06 AM
$SPRY Stone isn't it time for a short interest update? You so graciously flooded the aqst board with constant short interest updates. If I recall the rise in SI was due to "big boy" positioning. What is happening with SPRY? How are the big boys positioning here?
1 · Reply
BigGainTom
BigGainTom Feb. 25 at 9:23 PM
$SPRY short interest up by 1M shares. $AQST Short interest down by 300k shares.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 1:20 PM
$SPRY RSI: 36.31, MACD: -0.3767 Vol: 0.51, MA20: 9.68, MA50: 10.48 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
prototyper
prototyper Feb. 24 at 8:31 PM
$SPRY Volume less than 500K. Expecting ER to be catastrophically bad. GL cuz you will need it
1 · Reply
Stone52
Stone52 Feb. 23 at 3:28 PM
$SPRY important to re-emphasize this additional stake. Rubric are folks from Steve Cohen’s Point 72 Asset Management. They know what they’re doing - and usually trade with information.
0 · Reply
ae1213
ae1213 Feb. 23 at 3:12 PM
$AQST $SPRY silly sally is trying so hard, it is really funny. In his desperation he can’t see things right in front of him
3 · Reply
Stone52
Stone52 Feb. 23 at 2:49 PM
$SPRY could be bought out by ALK-Abello, their partner ex-US, who has a 45 Billion market cap. On ALK-Abello conference call Friday, they said their 2026 focus is Neffy - but that it has lower margins (due to royalties), so the company guided for lower margins overall. How to rectify? Buy ARS.
0 · Reply
BigGainTom
BigGainTom Feb. 21 at 5:29 PM
$SPRY Posting this here for investors in nasal spray Epi products. $NSRX does not seem to have a ST page. https://finance.yahoo.com/news/nasus-pharma-participate-upcoming-investor-130000668.html
0 · Reply
UgoGreg
UgoGreg Feb. 21 at 4:21 PM
$SPRY https://youtu.be/ygBN8MilTyc
0 · Reply
BigGainTom
BigGainTom Feb. 21 at 4:05 PM
$AQST $SPRY Not sure why they don't have a listing on Stocktwits. But it is apparently listed on NYSE. They have a nasal spray competitor to Neffy that works faster... I think it will destroy Neffy. https://finance.yahoo.com/quote/NSRX/
2 · Reply
DwayneKnotts654
DwayneKnotts654 Feb. 21 at 6:46 AM
$SPRY ARK Genomic Revolution ETF exposure to biotech innovation. Performance is sentiment-driven. Volatility is elevated.
0 · Reply
prototyper
prototyper Feb. 21 at 12:24 AM
$SPRY Going down to $3-4 soon
0 · Reply
History101
History101 Feb. 20 at 6:53 PM
$SPRY recent price action shows market is favoring $AQST over SPRY...GLTALs in both!!
1 · Reply
BigGainTom
BigGainTom Feb. 20 at 5:31 PM
$SPRY Huge competitor to SPRY is $NSRX. Their nasal spray works much faster than Neffy. Certainly we already know that $AQST's Anaphylm also works much faster than Neffy. Neffy is basically dead.
2 · Reply
BigGainTom
BigGainTom Feb. 19 at 5:40 PM
$AQST $SPRY Still it is only a competitor to Neffy. There is no other oral film other than Anaphylm that is even close to commercialization.
0 · Reply
EileenUbendenlick
EileenUbendenlick Feb. 19 at 2:55 PM
$AQST $SPRY @WallStWireAds
2 · Reply